Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era
Level 1 evidence supports a survival benefit to cytoreductive nephrectomy (CN) followed by cytokine therapy in patients with metastatic renal cell carcinoma (mRCC) [1 –3]. Although comparable randomized data do not exist for patients treated with targeted therapies, several retrospective studies suggest a similar survival benefit for CN [4–6]. However, it is unclear whether selection criteria and treatment sequencing paradigms developed during the immunothera py era are applicable to patients treated within the contemporary targeted therapy era.
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Timothy D. Lyon, Boris Gershman, Paras H. Shah, R. Houston Thompson, Stephen A. Boorjian, Christine M. Lohse, Brian A. Costello, John C. Cheville, Bradley C. Leibovich Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Cytokine Therapy | Kidney Cancer | Nephrectomy | Renal Cell Carcinoma | Study | Urology & Nephrology